The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab
A predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC.
Authors
- Yaolin Chen
- Fei Gao (ORCID: https://orcid.org/0000-0003-3633-3133)
- Wenxi Dang (ORCID: https://orcid.org/0000-0003-3553-7556)
- Yifu He (ORCID: https://orcid.org/0009-0005-8257-1230)
- Hao Shen (ORCID: https://orcid.org/0000-0003-3368-9185)
- Xudong Liu (ORCID: https://orcid.org/0000-0003-2911-4899)
- Zhihua Zhang (ORCID: https://orcid.org/0009-0002-5298-5078)
- Haoyu Wang (ORCID: https://orcid.org/0000-0002-9882-2752)
- Zhen Cai (ORCID: https://orcid.org/0000-0001-6026-3804)
- Shusheng Wu (ORCID: https://orcid.org/0000-0003-1084-8630)
- Mengge Li (ORCID: https://orcid.org/0000-0003-1337-1823)
- Mingjie Sun (ORCID: https://orcid.org/0009-0000-1800-0381)
Institutions
- Wannan Medical College (CN)
- University of Science and Technology of China (CN)
- Anhui Medical University (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-11-18
- DOI
- https://doi.org/10.1080/14796694.2024.2430160
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00